Literature DB >> 15649697

ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.

Barbara L Trommer1, Chirag Shah, Sung Hwan Yun, Georgi Gamkrelidze, Emily S Pasternak, W Blaine Stine, Arlene Manelli, Patrick Sullivan, Joseph F Pasternak, Mary Jo LaDu.   

Abstract

Amyloid-beta1-42 (Abeta1-42) is crucial to Alzheimer disease (AD) pathogenesis but the conformation of the toxic Abeta species remains uncertain. AD risk is increased by apolipoprotein E4 (apoE4) and decreased by apoE2 compared with the apoE3 isoform, but whether inheritance of apoE4 represents a gain of negative or a loss of protective function is also unresolved. Using hippocampal slices from apoE knockout (apoE-KO) and human apoE2, E3, and E4 targeted replacement (apoE-TR) mice, we found that oligomeric Abeta1-42 inhibited long-term potentiation (LTP) with a hierarchy of susceptibility mirroring clinical AD risk (apoE4-TR > apoE3-TR = apoE-KO > apoE2-TR), and that comparable doses of unaggregated Abeta1-42 did not affect LTP. These data provide a novel link among apoE isoform, Abeta1-42, and a functional cellular model of memory. In this model, apoE4 confers a gain of negative function synergistic with Abeta1-42, apoE2 is protective, and the apoE-Abeta interaction is specific to oligomeric Abeta1-42.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15649697     DOI: 10.1016/j.nbd.2004.08.011

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  39 in total

1.  Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype.

Authors:  John M Ringman; David Elashoff; Daniel H Geschwind; Brian T Welsh; Karen H Gylys; Cathy Lee; Jeffrey L Cummings; Greg M Cole
Journal:  Arch Neurol       Date:  2012-06

2.  Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele.

Authors:  Nicola Filippini; Bradley J MacIntosh; Morgan G Hough; Guy M Goodwin; Giovanni B Frisoni; Stephen M Smith; Paul M Matthews; Christian F Beckmann; Clare E Mackay
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-08       Impact factor: 11.205

3.  A β-amyloid oligomer directly modulates P/Q-type calcium currents in Xenopus oocytes.

Authors:  M Mezler; S Barghorn; H Schoemaker; G Gross; V Nimmrich
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

4.  Apolipoprotein E-low density lipoprotein receptor interaction affects spatial memory retention and brain ApoE levels in an isoform-dependent manner.

Authors:  Lance A Johnson; Reid H J Olsen; Louise S Merkens; Andrea DeBarber; Robert D Steiner; Patrick M Sullivan; Nobuyo Maeda; Jacob Raber
Journal:  Neurobiol Dis       Date:  2014-01-09       Impact factor: 5.996

Review 5.  Huntington's Disease.

Authors:  Steven Finkbeiner
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-06-01       Impact factor: 10.005

Review 6.  Apolipoprotein E in Alzheimer's disease and other neurological disorders.

Authors:  Philip B Verghese; Joseph M Castellano; David M Holtzman
Journal:  Lancet Neurol       Date:  2011-03       Impact factor: 44.182

Review 7.  Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity.

Authors:  Roberto Cappai; Kevin J Barnham
Journal:  Neurochem Res       Date:  2007-08-31       Impact factor: 3.996

8.  APOE4-specific changes in Aβ accumulation in a new transgenic mouse model of Alzheimer disease.

Authors:  Katherine L Youmans; Leon M Tai; Evelyn Nwabuisi-Heath; Lisa Jungbauer; Takahisa Kanekiyo; Ming Gan; Jungsu Kim; William A Eimer; Steve Estus; G William Rebeck; Edwin J Weeber; Guojun Bu; Chunjiang Yu; Mary Jo Ladu
Journal:  J Biol Chem       Date:  2012-10-11       Impact factor: 5.157

9.  Endocytic pathways mediating oligomeric Abeta42 neurotoxicity.

Authors:  Chunjiang Yu; Evelyn Nwabuisi-Heath; Kevin Laxton; Mary Jo Ladu
Journal:  Mol Neurodegener       Date:  2010-05-17       Impact factor: 14.195

10.  An update on the toxicity of Abeta in Alzheimer's disease.

Authors:  Jürgen Götz; Lars M Ittner; Nicole Schonrock; Roberto Cappai
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.